Cinacalcet Tablet, Film Coated
Product Images NDC 31722-103

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 31722-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 mg Container (30 mg Container)

Cinacalcet Tablets 30 mg film-coated oral tablets label by Camber Pharmaceuticals, Inc. The label indicates a package size of 30 tablets and includes a barcode. Storage instructions specify 20° to 25°C. Manufacturer information for Hetero Labs Limited, India, is also included.*

FDA Label Image

60 mg Container (60 mg Container)

Cinacalcet Tablets 60 mg film-coated oral tablets label showing the product name, strength, and quantity of 30 tablets. The label includes storage instructions (20° to 25°C), manufacturer information (Camber Pharmaceuticals, Inc.), and a barcode. It also displays the NDC 31722-104-30 and emphasizes that the tablets are prescription only.*

FDA Label Image

90 mg Container (90 mg Container)

Label for Cinacalcet Tablets 90 mg, film-coated oral tablets, containing 30 tablets per container. The label shows the product name, strength, quantity, and NDC number 31722-105-30, with a blue background behind the strength. It lists Camber Pharmaceuticals, Inc. as the labeler and Hetero Labs Limited as the manufacturer. Additional storage and handling instructions are printed, including storage at 20° to 25°C and dispensing in a tight, light-resistant container.*

FDA Label Image

Camber (Camber)

FDA Label Image

Figure-of-cinacalcet-1 (Figure Of Cinacalcet 1)

A line graph comparing intact parathyroid hormone (iPTH) levels (pg/mL) over 26 weeks between placebo and Cinacalcet treatment groups. The x-axis represents weeks, and the y-axis represents iPTH levels. Cinacalcet shows a decreasing iPTH trend while placebo remains relatively stable.*

FDA Label Image

Figure-of-cinacalcet-2 (Figure Of Cinacalcet 2)

A line graph comparing Ca x P (mg/dL)2 levels over 26 weeks between placebo and Cinacalcet treatment groups. The y-axis represents Ca x P concentration, and the x-axis represents the duration in weeks. The graph shows trends of both groups with error bars indicating variability.*

FDA Label Image

Figure3 (Figure3)

A line graph depicting serum calcium levels (mg/dL) over 80 weeks in patients with parathyroid carcinoma. The x-axis represents time in weeks, including titration, end of titration, and maintenance phases. The y-axis shows calcium concentration, with data points and error bars indicating variability. Patient counts per time point are listed below the axis.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting calcium levels (mg/dL) over weeks of treatment, showing initial titration and subsequent maintenance phases. The x-axis represents weeks from baseline to week 80, and the y-axis represents calcium concentration. Data points include error bars indicating variability, and the number of participants at each time point is noted below the x-axis.*

FDA Label Image

Structure (Structure)

Chemical structure of Cinacalcet hydrochloride, the active ingredient in the drug Cinacalcet. The diagram depicts the molecular arrangement including aromatic rings, a trifluoromethyl group, and a hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.